RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @MRMehraMD: No harm of RAAS inhibitors in COVID - Potential benefit with ACE Inhibitors and Statins? Do these hypothesis generating find…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
Good info against bad assumptions
RT @mayogastro: Padecer de enfermedad cardiovascular es el factor de riesgo más importante de severidad en CoViD-19. Cuidados extremos en e…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
@jiw1374 👍
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @ethanjweiss: Maybe don't stop the statin? https://t.co/Gnp9WieRc1 https://t.co/iqX9ZGiGSJ
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/kDyYIDjlsM Important findings by @MRMehraMD et al https://t.co/CSRblLTVjI
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/KimZ81lTq5
RT @EricTopol: Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM ap…
RT @JorgeRubenO: 🔷 La enfermedad cardiovascular subyacente se asocia con un mayor riesgo de muerte en el hospital en pacientes #COVID19 🔶…
Remember the early hysteria about ACE inhibitors putting patients w/ #COVID19 at risk? That was a wrong turn. 3 new @NEJM appears and editorial today: There is no evidence these drugs or ARBs have any detrimental effect. https://t.co/Mzc7SUKTKb https://t.
Article in @NEJM by @HenrytTimothy and colleagues confirms previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospitalized with COVID-19.
RT @MRMehraMD: No harm of RAAS inhibitors in COVID - Potential benefit with ACE Inhibitors and Statins? Do these hypothesis generating find…
Important new data regarding ACEi and ARBs on COVID-19 in-hospital mortality.
@NEJM Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/7CnsPVhr7a
Another large observational study showing no increased risk from Ace Inhibitors or ARBs and possible protective effects from Ace Inhibitors. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/mJZxfMyxyU
Un estudio publicado en el NEJM sugiere que las mujeres son más resistentes a Covid-19 que los hombres. Para los autores, las mujeres podrían tener una inmunidad innata y/o adaptativa más fuerte frente al virus. #Covid_19 https://t.co/giIgdYQrzk https://t
RT @MRMehraMD: No harm of RAAS inhibitors in COVID - Potential benefit with ACE Inhibitors and Statins? Do these hypothesis generating find…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM #COVID19 https://t.co/3iL1GZEGPp
RT @GilbertDeray: Les barres à droite de la ligne verticale indiquent les facteurs qui augmente le risque de mortalité intra hospitalière.…
RT @DavidJuurlink: Three new studies in @NEJM on the safety of ACE inhibitors/ARBs in COVID-19 https://t.co/kFfescrB6f https://t.co/YXbFw…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/YfYbCMTcq6
Inhibitors of the Renin–Angiotensin–Aldosterone System #ACEIs #ARBs and #COVID19 @NEJM - Mehra et al. https://t.co/WbwUDTgGw0 - Mancia et al. https://t.co/KNHABU5yTK - Reynolds et al. https://t.co/zRAa0ofg86 - Jarcho et al. [Editorial] https://t.co/jMw
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/hRQiZr3V3k
New England Journal of Medicine 8910 #COVID19 Patients w/ 515 Fatalities Preexisting increased risk: >65 years 10.0% Coronary Artery Fisease 10.2% Heart Failure 15.3% Arrhythmia 11.5% COPD 14.2% Current smoker 9.4% https://t.co/muykqoTGmp #MSNBC #MAGA
RT @Azeem_Majeed: Another reason to stop smoking. Risk factors for death in hospital patients with Covid-19 in an international study publi…
COVID19 hastalığı seyri boyunca ya da öncesi tansiyon kontrolü için alınan ACE inhibitörleri hastalığın seyrini olumsuz etkilemez. Güvenle kullanılabilinir. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/CHy2d5wFR1
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/0tvwNFNEvS
RT @PharmERToxGuy: Three new large population studies in @NEJM find ACE-Inhibitors and ARBs do NOT increase risk of #COVID19. Cardiovascula…
VOA RAMIPRIL!
RT @MRMehraMD: No harm of RAAS inhibitors in COVID - Potential benefit with ACE Inhibitors and Statins? Do these hypothesis generating find…
RT @MRMehraMD: No harm of RAAS inhibitors in COVID - Potential benefit with ACE Inhibitors and Statins? Do these hypothesis generating find…
RT @mayogastro: Padecer de enfermedad cardiovascular es el factor de riesgo más importante de severidad en CoViD-19. Cuidados extremos en e…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 https://t.co/g7bdoX37uG
RT @DavidJuurlink: Three new studies in @NEJM on the safety of ACE inhibitors/ARBs in COVID-19 https://t.co/kFfescrB6f https://t.co/YXbFw…
New data by @HenrytTimothy and colleagues in @NEJM from 169 hospitals with 8910 COVID+ patients shows an in-hospital mortality rate of 5.8% and a protective effect of ACE inhibitors and statins https://t.co/ANB2ncSZzL https://t.co/84V12LP2PS
Vaikuttaisi hyviltä uutisilta verenpainelääkettä käyttäville. Tästäkin on ollut pitkään epäselvyyttä. https://t.co/b3MWMpJARF
Good to see that ACEI/ARB continues to be mortality neutral, possible signal for ACEI protection, though association only Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/HM5vpkjdTt
RT @MRMehraMD: No harm of RAAS inhibitors in COVID - Potential benefit with ACE Inhibitors and Statins? Do these hypothesis generating find…
RT @GilbertDeray: Les barres à droite de la ligne verticale indiquent les facteurs qui augmente le risque de mortalité intra hospitalière.…
🔷 La enfermedad cardiovascular subyacente se asocia con un mayor riesgo de muerte en el hospital en pacientes #COVID19 🔶El uso de IECA/ARAII no se asociaron con un mayor riesgo de muerte en el hospital. https://t.co/vLyJVQWmJZ
RT @AndyBiotech: Three studies in NEJM found no evidence of harm with continued use of ACEi and ARBs in #COVID19 pts w/ hypertension N=891…
RT @DavidJuurlink: Three new studies in @NEJM on the safety of ACE inhibitors/ARBs in COVID-19 https://t.co/kFfescrB6f https://t.co/YXbFw…
RT @FormigaFrancesc: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/iN5mVVgq4H
RT @AndyBiotech: Three studies in NEJM found no evidence of harm with continued use of ACEi and ARBs in #COVID19 pts w/ hypertension N=891…
bu çalışmaya göre diüretikler çok daha riskli :) ama toplumda kaç kişinin ACE ARB kalsiyum kanal blokeri diüretik ve betabloker kullandığını belirtip ona göre yüzde kaçı hasta olmus , rısk faktörü olup olmadığı gerekmezmi _
RT @CharlieTomson: Three papers confirming what @RenalAssoc @escardio and others said all along: RAS inhibitors do not make people more lik…
RT @DavidJuurlink: Three new studies in @NEJM on the safety of ACE inhibitors/ARBs in COVID-19 https://t.co/kFfescrB6f https://t.co/YXbFw…
RT @CharlieTomson: Three papers confirming what @RenalAssoc @escardio and others said all along: RAS inhibitors do not make people more lik…
#CCC19 #oncoalert Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/dHsKaFJAD9 Underlying cardiovascular disease associated with increased risk of mortality among patients hospitalized with Covid-19 @nicolekuderer @pergamI
RT @CharlieTomson: Three papers confirming what @RenalAssoc @escardio and others said all along: RAS inhibitors do not make people more lik…
RT @AndyBiotech: Three studies in NEJM found no evidence of harm with continued use of ACEi and ARBs in #COVID19 pts w/ hypertension N=891…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/VXRHrKhfgO
RT @ethanjweiss: Maybe don't stop the statin? https://t.co/Gnp9WieRc1 https://t.co/iqX9ZGiGSJ
RT @Azeem_Majeed: Another reason to stop smoking. Risk factors for death in hospital patients with Covid-19 in an international study publi…
RT @ethanjweiss: Maybe don't stop the statin? https://t.co/Gnp9WieRc1 https://t.co/iqX9ZGiGSJ
RT @ethanjweiss: Maybe don't stop the statin? https://t.co/Gnp9WieRc1 https://t.co/iqX9ZGiGSJ
COVID-19の世界8,910入院症例の症例対照研究。65歳以上、冠動脈疾患、心不全、不整脈、COPD、喫煙習慣はそれぞれ死亡リスク増大。ACEIやARB服用では増大なしと。 Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/88DffAWWL6
RT @MRMehraMD: Many Questions, Varying Opinions, now some data-driven answers - How do Cardiac Medications modify outcome in COVID-19? Card…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 | NEJM https://t.co/5fhaZr6ngu
RT @CharlieTomson: Three papers confirming what @RenalAssoc @escardio and others said all along: RAS inhibitors do not make people more lik…
RT @AndyBiotech: Three studies in NEJM found no evidence of harm with continued use of ACEi and ARBs in #COVID19 pts w/ hypertension N=891…
@CircAHA @JAMA_current @NEJM @Dereklowe @ScienceMagazine #COVID19 Continued evidence of no harm with the use of ACE inhibitors and ARBs in COVID-19 patients with hypertension across multiple large studies. @NEJM https://t.co/aXaiw7mong
RT @GilbertDeray: Les barres à droite de la ligne verticale indiquent les facteurs qui augmente le risque de mortalité intra hospitalière.…
Work well done by @MRMehraMD and friends on cardiovascular risk factors for #COVID19 mortality. But I'm curious to know where CKD fits in! https://t.co/BhbYiyoviI
コロナウイルスは、女性の方が死ぬリスクが小さいことはかなり言われてきているが、それ以上に、高血圧治療薬ACE阻害剤や高脂血症治療薬スタチン系薬剤の服用者が死ぬリスク小さい。#コロナウイルス https://t.co/kZ86YtrHzG
Three papers confirming what @RenalAssoc @escardio and others said all along: RAS inhibitors do not make people more likely to acquire COVID19 nor to die from it https://t.co/MRLYYqFESh https://t.co/fNOPtEZ8Yt https://t.co/UKm7aRqaFj https://t.co/q7mQPjy67
RT @MRMehraMD: Many Questions, Varying Opinions, now some data-driven answers - How do Cardiac Medications modify outcome in COVID-19? Card…
RT @ABsteward: In this large population based study @NEJM Using database from 169 hospitals in Asia, Europe, and North America"~9000 patien…
Three studies in NEJM found no evidence of harm with continued use of ACEi and ARBs in #COVID19 pts w/ hypertension N=8910 Multinational study https://t.co/vlOEZTUnrt N=6272 Lombardy https://t.co/mNEsvxtI2i N=5894 NYC https://t.co/cBd3kUYcns Editorial
RT @MRMehraMD: No harm of RAAS inhibitors in COVID - Potential benefit with ACE Inhibitors and Statins? Do these hypothesis generating find…
RT @ABsteward: In this large population based study @NEJM Using database from 169 hospitals in Asia, Europe, and North America"~9000 patien…
RT @PharmERToxGuy: Three new large population studies in @NEJM find ACE-Inhibitors and ARBs do NOT increase risk of #COVID19. Cardiovascula…
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19: did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context. https://t.co/JYrnjjO6BP
RT @ABsteward: In this large population based study @NEJM Using database from 169 hospitals in Asia, Europe, and North America"~9000 patien…
RT @DavidJuurlink: Three new studies in @NEJM on the safety of ACE inhibitors/ARBs in COVID-19 https://t.co/kFfescrB6f https://t.co/YXbFw…
RT @MRMehraMD: Many Questions, Varying Opinions, now some data-driven answers - How do Cardiac Medications modify outcome in COVID-19? Card…
RT @GilbertDeray: Les barres à droite de la ligne verticale indiquent les facteurs qui augmente le risque de mortalité intra hospitalière.…
RT @MRMehraMD: Many Questions, Varying Opinions, now some data-driven answers - How do Cardiac Medications modify outcome in COVID-19? Card…
RT @ABsteward: In this large population based study @NEJM Using database from 169 hospitals in Asia, Europe, and North America"~9000 patien…
RT @ABsteward: In this large population based study @NEJM Using database from 169 hospitals in Asia, Europe, and North America"~9000 patien…
RT @DavidJuurlink: Three new studies in @NEJM on the safety of ACE inhibitors/ARBs in COVID-19 https://t.co/kFfescrB6f https://t.co/YXbFw…
(NEJM) Edad >64 años, cardiopatía isquémica, insuficiencia cardíaca, arritmia cardíaca, EPOC y tabaquismo se asociaron a mayor riesgo de muerte entre los pacientes hospitalizados por #Covid19 IECA o ARA2 no (8910 pacientes) https://t.co/DfyDF44eAa